Related Experiment Videos
Aberrant acute-phase response in aged interleukin-6 knockout mice.
Christian R Gomez1, Joanna Goral, Luis Ramirez
1Department of Cell Biology, Neurobiology, and Anatomy, The Burn and Shock Trauma Institute, Alcohol Research Program, and Immunology and Aging Program, Loyola University Medical Center, Maywood, IL 60130, USA.
Shock (Augusta, Ga.)
|May 25, 2006
Summary
Interleukin-6 (IL-6) deficiency improves survival in aged mice challenged with lipopolysaccharide (LPS). The absence of IL-6 reduces the acute-phase response, enhancing resilience in aging individuals.
Area of Science:
- Immunology
- Aging Research
- Inflammation Biology
Background:
- Aging is associated with an altered acute-phase response.
- Interleukin-6 (IL-6) contributes to the basal proinflammatory state in aging.
- The role of IL-6 in the aged acute-phase response to endotoxin is not fully understood.
Purpose of the Study:
- To investigate the impact of interleukin-6 (IL-6) deficiency on the acute-phase response in aged mice.
- To compare the survival rates and inflammatory markers between aged wild-type (WT) and IL-6 knockout (KO) mice following lipopolysaccharide (LPS) challenge.
Main Methods:
- Young and aged WT and IL-6 KO BALB/C female mice were administered LPS.
- Survival rates were assessed 24 hours post-LPS injection.
- Serum levels of IL-6, serum amyloid A (SAA), LPS-binding protein (LBP), and corticosterone were measured.
Main Results:
- Aged IL-6 KO mice exhibited improved survival compared to aged WT mice after LPS challenge.
- Serum amyloid A levels were significantly lower in aged LPS-treated IL-6 KO mice versus aged WT mice.
- LPS-binding protein induction was unaffected by age or IL-6 status.
- Corticosterone levels were markedly reduced in aged LPS-treated IL-6 KO mice.
Conclusions:
- Interleukin-6 (IL-6) plays a critical role in the outcome of the acute-phase response in aged individuals challenged with endotoxin.
- IL-6 deficiency enhances the ability of aged mice to survive a lethal endotoxin challenge.
- Targeting IL-6 may be a strategy to mitigate age-related inflammatory responses and improve resilience.